Glow-in-the-Dark dye could help surgeons spot hidden ovarian cancer

NCT ID NCT05804370

Recruiting now Diagnosis Sponsor: NX Development Corp Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery. The goal is to help surgeons find and remove tumors they might otherwise miss. About 170 women with suspected or recurrent ovarian cancer will take part. The study lasts about two weeks per person.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

CAMC Institute for Academic Medicine - Cancer Research Center
RECRUITING

Charleston, West Virginia, 25304, United States
Luminis Health Anne Arundel Medical Center
COMPLETED

Annapolis, Maryland, 21401, United States
Mayo Clinic Arizona
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic Methodist Campus
RECRUITING

Rochester, Minnesota, 55905, United States
Mount Sinai
RECRUITING

New York, New York, 10128, United States
Riverside Health
RECRUITING

Newport News, Virginia, 23606, United States
The Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44195, United States
University of Maryland
RECRUITING

Baltimore, Maryland, 21201, United States
WVU Cancer Institute
NOT_YET_RECRUITING

Morgantown, West Virginia, 26506, United States
WellSpan Health
RECRUITING

York, Pennsylvania, 17403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.